PURPOSE: Oxaliplatin-induced neuropathy is a dose-related side effect which occurs in almost 40 % of patients treated with oxaliplatin. Aim of the present study was to identify reliable clinical factors predicting its development and duration. METHODS: One hundred sixty-nine completely resected colorectal cancer patients treated with adjuvant Folfox IV regimen were retrospectively included. The following pre-treatment clinical parameters were collected: hypocalcaemia, hypomagnesaemia, hypoalbuminaemia, anaemia, diabetes, chronic renal failure (CRF), folate deficiency, vitamin B(12) deficiency, number of cycles received and habit to alcohol consumption. Incidence, grade (NCI-CTCAE v.3) and duration of neuropathy were recorded. RESULTS: Incidence of neuropathy was found to be higher in patients with pre-treatment anaemia (p = 0.001), hypoalbuminaemia (p = 0.01) and hypomagnesaemia (p = 0.001) as well in those with habit to alcohol consumption (p = 0.003). Neuropathy durations were conversely associated with age, being longer in younger patients (p = 0.03), and again with hypoalbuminaemia (p = 0.04) and hypomagnesaemia (p = 0.002). No correlation was found with gender, hypocalcaemia, diabetes and CRF. The correlation between vitamin B(12) and folate levels and the development of neurotoxicity were not analysed because of the high number of missing data in the population. CONCLUSIONS: Age, anaemia, hypoalbuminaemia, hypomagnesaemia and alcohol consumption are reliable and easily assessable clinical factors predicting incidence and length of oxaliplatin-induced neuropathy.
PURPOSE:Oxaliplatin-induced neuropathy is a dose-related side effect which occurs in almost 40 % of patients treated with oxaliplatin. Aim of the present study was to identify reliable clinical factors predicting its development and duration. METHODS: One hundred sixty-nine completely resected colorectal cancerpatients treated with adjuvant Folfox IV regimen were retrospectively included. The following pre-treatment clinical parameters were collected: hypocalcaemia, hypomagnesaemia, hypoalbuminaemia, anaemia, diabetes, chronic renal failure (CRF), folate deficiency, vitamin B(12) deficiency, number of cycles received and habit to alcohol consumption. Incidence, grade (NCI-CTCAE v.3) and duration of neuropathy were recorded. RESULTS: Incidence of neuropathy was found to be higher in patients with pre-treatment anaemia (p = 0.001), hypoalbuminaemia (p = 0.01) and hypomagnesaemia (p = 0.001) as well in those with habit to alcohol consumption (p = 0.003). Neuropathy durations were conversely associated with age, being longer in younger patients (p = 0.03), and again with hypoalbuminaemia (p = 0.04) and hypomagnesaemia (p = 0.002). No correlation was found with gender, hypocalcaemia, diabetes and CRF. The correlation between vitamin B(12) and folate levels and the development of neurotoxicity were not analysed because of the high number of missing data in the population. CONCLUSIONS: Age, anaemia, hypoalbuminaemia, hypomagnesaemia and alcohol consumption are reliable and easily assessable clinical factors predicting incidence and length of oxaliplatin-induced neuropathy.
Authors: J P Durand; G Deplanque; V Montheil; J M Gornet; F Scotte; O Mir; A Cessot; R Coriat; E Raymond; E Mitry; P Herait; Y Yataghene; F Goldwasser Journal: Ann Oncol Date: 2011-03-22 Impact factor: 32.976
Authors: Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: R K Ramanathan; M L Rothenberg; A de Gramont; C Tournigand; R M Goldberg; S Gupta; T André Journal: Ann Oncol Date: 2009-11-03 Impact factor: 32.976
Authors: Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Hong-Hee Won; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Jong-Won Kim; Soo-Youn Lee; Se Hoon Park Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Sina Vatandoust; Rohit Joshi; Kenneth B Pittman; Adrian Esterman; Vy Broadbridge; Jacqueline Adams; Nimit Singhal; Susan Yeend; Timothy Jay Price Journal: Support Care Cancer Date: 2014-02 Impact factor: 3.603
Authors: M Eileen Dolan; Omar El Charif; Heather E Wheeler; Eric R Gamazon; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Jeri Kim; Sophie D Fossa; Daniel L Hertz; Taisei Mushiroda; Michiaki Kubo; Lawrence H Einhorn; Nancy J Cox; Lois B Travis Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: Pauline A J Vissers; Floortje Mols; Melissa S Y Thong; Frans Pouwer; Gerard Vreugdenhil; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2015-02-03 Impact factor: 4.442
Authors: Kim L Dittus; Susan G Lakoski; Patrick D Savage; Nathan Kokinda; Michael Toth; Diane Stevens; Kimberly Woods; Patricia OʼBrien; Philip A Ades Journal: J Cardiopulm Rehabil Prev Date: 2015 Mar-Apr Impact factor: 2.081
Authors: Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-08 Impact factor: 10.154
Authors: Paul A Glare; Pamela S Davies; Esmé Finlay; Amitabh Gulati; Dawn Lemanne; Natalie Moryl; Kevin C Oeffinger; Judith A Paice; Michael D Stubblefield; Karen L Syrjala Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José M Castro-Lopes; Nuno Lunet Journal: Support Care Cancer Date: 2015-09-18 Impact factor: 3.603